ALNYAlnylam Pharmaceuticals, Inc.

CSNasdaq (XNAS)·USD

Identity

Security key: 11599
Ticker: ALNY
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2004-05-28
Round lot: 40
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: ALNY

Detail

Enriched 2026-08-14 20:47

Market cap: $29,966,551,976.1
Shares outstanding (class): 133,809,118
Shares outstanding (weighted): 133,809,118
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 2,500
Location: CAMBRIDGE, MA
Homepage: https://www.alnylam.com
Description: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Market cap and share counts drift.

Funds holding this security

369 funds · 374 positions · $13.75B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$1.39B	0.07%	4,215,761 NS	FIGI
VANGUARD MID-CAP INDEX FUND VANGUARD INDEX FUNDS	VO	$947.66M	0.48%	2,864,161 NS	FIGI
Invesco QQQ Trust, Series 1 Invesco QQQ Trust, Series 1	QQQ	$924.39M	0.25%	2,793,810 NS	FIGI
JPMorgan Large Cap Growth Fund JPMorgan Trust II	—	$673.85M	0.63%	2,036,592 NS	FIGI
Investment Co of America Investment Co of America	—	$644.46M	0.39%	1,947,787 NS	FIGI
T. Rowe Price Capital Appreciation Fund T. ROWE PRICE CAPITAL APPRECIATION FUND, IN…	—	$567.73M	0.86%	1,715,880 NS	FIGI
VANGUARD GROWTH INDEX FUND VANGUARD INDEX FUNDS	VUG	$517.89M	0.16%	1,565,234 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$489.77M	0.60%	1,480,260 NS	FIGI
Growth Fund AMERICAN FUNDS INSURANCE SERIES	—	$422.35M	0.85%	1,276,486 NS	FIGI
Dodge & Cox Stock Fund Dodge & Cox Funds	—	$408.03M	0.36%	1,233,200 NS	FIGI
Fidelity Contrafund Fidelity Contrafund	—	$398.03M	0.25%	1,202,994 NS	FIGI
T. Rowe Price Mid-Cap Growth Fund, Inc. T. ROWE PRICE MID-CAP GROWTH FUND, INC.	—	$385.98M	1.71%	1,166,560 NS	FIGI
New Perspective Fund New Perspective Fund	—	$337.59M	0.22%	1,020,320 NS	FIGI
VANGUARD MID-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VOT	$333.76M	1.14%	1,008,744 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$324.13M	3.99%	979,642 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERALNY
FIGI_COMPOSITEBBG000BFGNJ5
FIGI_SHARE_CLASSBBG001S7FTC8
CIK0001178670
ISINUS02043Q1076
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Alnylam is a biopharmaceutical company focused on RNAi therapeutics, classified under pharmaceuticals.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.